35 results about "Endometrial tissue" patented technology

The invention discloses pyruvate carboxylase (PC) serving as a biomarker for detecting endometriosis and application of the pyruvate carboxylase (PC) to treatment of the endometriosis. The biomarker can be used for detecting the expression level of PC in an endometrial tissue sample through an immunohistochemical method, and when the IHC score is greater than or equal to 4, a subject is judged to be at a high risk of endometriosis or suffered from the endometriosis. Meanwhile, the invention provides an application of drugs (including specific siRNA, ZY-444, octyl gallate and the like) for inhibiting PC expression in treatment of endometriosis, and a corresponding treatment method. The invention provides a new biomarker, target spot and scheme for detection and treatment of endometriosis, and has important clinical application value.

The invention discloses a Raman spectrum-based endometrial tissue spectral data processing method and equipment, and relates to the technical field of data processing. The method comprises the following steps: firstly, calculating a gradient change sequence of to-be-processed spectral data, carrying out continuity verification in combination with wavelength and width, and accurately dividing a Raman characteristic peak interval and a background baseline interval; then, iterative baseline fitting processing based on a Raman peak protection mechanism is adopted, blood fluorescence interference is eliminated, and pure Raman spectrum data is obtained. And further, inputting the pure spectral data into a pre-constructed segmented fusion feature extraction network, extracting local wave band features, fusing the local wave band features with global features, and outputting a data classification result. According to the embodiment of the invention, the problem of difficult feature extraction caused by low signal-to-noise ratio of a bleeding sample and non-uniform background in related technologies can be effectively solved, the integrity of spectrum fingerprint information is ensured while strong fluorescence interference is thoroughly eliminated, and the accuracy of data feature extraction and the robustness of classification and recognition are improved.

The invention relates to the technical field of medical care information processing, and discloses a traditional Chinese medicine prescription efficacy evaluation system for treating intrauterine adhesion, comprising: a data preprocessing module for acquiring endometrial dynamic response gray time sequence characteristic data before and after a subject takes a prescription; the phase analysis module is used for determining a phase deviation distribution coefficient according to the phase angle distribution of the gray scale data of the reference pixel and the response pixel; the frequency domain inversion module is used for constructing an energy transfer gain spectrum by calculating a power ratio and identifying a characteristic resonant frequency; the evaluation index output module is used for generating an evaluation index for evaluating the viscoelasticity improvement degree of the endometrial tissue according to the deviation value of the characteristic resonant frequency in combination with the variation of the phase deviation distribution coefficient. And the quantitative accuracy of evaluation is improved.

A method and apparatus for analyzing one or more MR images showing a pelvic region to identify features indicative of a region containing endometrial tissue is described. The method comprises the steps of: acquiring one or more quantitative non-contrast MR medical image scans of the pelvic region; determining one or more MR metrics to determine one or more multi-parameter MR maps of the pelvic region; and analyzing the multi-parameter MR map to determine a biomarker indicative of a region of abnormal iron concentration.

Disclosed herein are methods for obtaining endometrial stromal fibroblast cells from pluripotent stem cells, such as induced pluripotent stem cells. The present disclosure also provides methods of obtaining a three-dimensional, multilayered endometrial tissue composition. Methods of using the cells and tissue compositions in drug screening and therapeutic applications are also provided.

An electrotherapeutic device can be configured for at least partial insertion into a patient. The device can include a shaft including a proximal portion and a distal portion, a gas-delivery lumen extending between the proximal portion and the distal portion of the shaft, and one or more electrodes located near the distal portion of the shaft. The electrodes can include a plasma activation electrode for generating plasma from gas delivered to the distal portion of the shaft via the gas-delivery lumen, and an ablation electrode for generating electromagnetic ablation energy. The medical device can be used in a method of treating endometriosis including delivering a gas toward an in vivo treatment site within a patient, generating plasma from the gas on or near the in vivo treatment site using a plasma activation electrode, exposing the treatment site to the plasma, and applying electromagnetic ablation energy to treat endometrial tissue.

The application belongs to the technical field of biotechnology and medicine, and specifically discloses a single-domain antibody-exosome compound (Nb-EMX2-Exos) targeting EMX2 as well as a preparation method and application thereof. The compound is prepared by covalently coupling a single-domain antibody (Nb-EMX2) specifically binding to EMX2 protein to the surface of endometrial stem cell-derived exosomes (ESC-Exos). In-vitro experiments show that the compound can specifically recognize and efficiently internalize into damaged endometrial stromal cells with high expression of EMX2, and significantly promote the migration and proliferation of the cells. In-vivo experiments further prove that the compound can precisely target and enrich in damaged endometrial tissue, effectively promote the structural repair (thicken the endometrium and reduce fibrosis) of the endometrium, and completely restore the fertility function. The application provides a novel targeted treatment preparation for solving the problems of poor targeting of natural exosomes and limited treatment effect, and has important application value in the treatment of endometrial injury repair and related infertility.

The invention discloses a model building method based on animal endometrial epithelium organoid and application of the model building method, and relates to the technical field of cell engineering and organoid. According to the method, healthy cow endometrial tissue serves as a raw material, a model is built through the steps of pretreatment, enzymolysis, cell cleaning and screening, seed gum culture, passage, cryopreservation resuscitation and the like, and the model is built through Hamp; e, verifying morphological integrity through dyeing, and detecting E-cadherin expression through IHC dyeing to confirm cell specificity. The animal organ model restores the in-vivo three-dimensional microenvironment and species specificity, overcomes the limitation of traditional two-dimensional culture and mouse models, can accurately simulate the pathological process of endometritis, is applied to research on the pathogenesis of endometritis of dairy cows, can also efficiently screen anti-inflammatory drugs and evaluate the drug effect, and has a wide application prospect. A reliable in-vitro tool is provided for disease prevention and treatment, and healthy development of the dairy cow breeding industry is assisted.

This invention belongs to the field of biotechnology, and particularly relates to the use of the SPON2 gene or its protein as a target in the diagnosis or treatment of endometriosis. Supported by multi-omics and single-cell level data and tested with clinical samples, this invention, for the first time, elucidates the correlation between SPON2 and endometriosis (EM), revealing that high expression of SPON2 in eutopic and ectopic endometrial fibroblasts in endometriosis patients enhances their proliferation, invasion, and migration abilities. Inhibiting SPON2 gene expression or inhibiting SPON2 protein function reduces the proliferation and invasion abilities of endometrial tissue, as well as lesion migration, invasion, and fibrosis, thus improving the condition of endometriosis. This suggests that the SPON2 gene or its protein can serve as a diagnostic or therapeutic target, providing new ideas and directions for the clinical diagnosis and targeted therapy of endometriosis.

The invention belongs to the technical field of application of traditional Chinese medicines, and particularly relates to application of a Dan'e Fukang preparation in preparation of a medicine for treating dysfunctional uterine bleeding. Pharmacological experiments prove that Dan'e'fukang can shorten the blood coagulation time and bleeding time of mice, and increase the uterine coefficient, estradiol level and progesterone level of rats without ovulation type dysfunctional uterine bleeding and the VEGF protein expression quantity of endometrial tissues of the rats. The Dan'e Fukang provides more medication choices for clinical treatment of dysfunctional uterine bleeding diseases, and has the advantages of good effect, many years of clinical use experience and high safety.

Provided herein include synthetic endometrial tissues and uterus-like structures for assessing embryo implantation and growth in vitro. Provided herein also include methods and devices for making the synthetic endometrial tissues and uterus-like structures and uses thereof to culture embryos (e.g., human embryos). The methods and synthetic endometrial tissues and structures generated herein can be used to culture pre-implantation embryos (e.g., human embryos) to reach a post-implantation stage.

This invention relates to the pharmaceutical field, specifically to a drug for the prevention or treatment of endometrial fibrosis, comprising poloxamer and spermidine; poloxamer is added to the spermidine solution and swelled at 3-5°C until completely dissolved to form a liquid precursor; the liquid precursor undergoes a phase transition at 35-40°C to form a gel; the liquid precursor is injected into the uterine cavity to reduce the expression of αSMA in the endometrial tissue, inhibit the transformation of stromal cells into myofibroblasts, and promote angiogenesis.

This invention belongs to the field of biomedical technology, specifically relating to the application of Danbie capsules in the preparation of products for treating endometriosis. This invention discovers that the combined use of Danbie capsules and progestins has a synergistic effect, with a superior intervention effect on endometrial stromal cells compared to a single component. Furthermore, this invention provides a traditional Chinese medicine-containing serum, the main medicinal components of which are quercetin and luteolin, which can effectively inhibit the growth and migration of endometrial stromal cells and induce apoptosis. This traditional Chinese medicine-containing serum is derived from Danbie capsules. Animal experiments have shown that Danbie capsules can inhibit the expression of AKT1 in endometrial tissue, and cell experiments have shown that the traditional Chinese medicine-containing serum can induce apoptosis of endometrial stromal cells, suggesting that the intervention effect of the traditional Chinese medicine Danbie capsules and its containing serum on endometrial stromal cells is related to AKT1 expression, providing an important insight into the relevant mechanism.

A hysteroscopic specimen collection device includes a connecting piece and a collection bag. The connecting piece has an operating through hole and a first adhesive layer on its back. The lower end of the connecting piece is connected to the opening side of the collection bag. A first filter and a second filter are installed sequentially from top to bottom inside the collection bag. The first filter is detachably installed inside the collection bag. The diameter of some filter holes in the second filter is smaller than the diameter of some filter holes in the first filter. A fixing plate is provided on the back of the connecting piece or the collection bag to assist in fixing the collection device during use. The first and second filters of this invention facilitate the separation of tissue specimens and distension fluid flowing into the collection bag, enabling specimen collection and separation of specimens of different sizes, such as easily separating uterine fibroid tissue and endometrial tissue. The first adhesive layer and the fixing plate together fix the collection device. The overall structure is simple, convenient, and practical.

The application provides application of a vitamin-magnesium compound in preparation of a medicine for preventing and treating miscarriage in a pregnant period and an early pregnant period and a preparation, relates to the technical field of biological medicines, and the vitamin-magnesium compound is a magnesium-based coordination chelate with a repairing effect on endometrial tissue. The vitamin-magnesium compound is an organic ligand of the magnesium-based coordination chelate, and the organic matter is any one of vitamin B13, vitamin B3 and vitamin C. The magnesium-based coordination chelate acts on endometrial stromal cells, promotes cell proliferation, and promotes normal implantation of an embryo. The magnesium-based coordination chelate acts on endometrial tissue vascular endothelial cells, promotes cell proliferation, and promotes angiogenesis to meet the nutritional supply of the embryo. The magnesium-based coordination chelate acts on endometrial tissue macrophages, M1 type macrophages are polarized into M2 type macrophages, immune tolerance to the embryo is promoted, and the normal growth and development of the embryo are prevented from being affected by the attack of maternal immune cells.

The application discloses a polypeptide AIUAP for preventing or assisting in preventing formation of intrauterine adhesion and application thereof. The polypeptide AIUAP for preventing, assisting in preventing or treating formation of intrauterine adhesion has an amino acid sequence of TFGGAPGFPLGSPLSSPVFPR (SEQ ID NO. 1), and is composed of 21 amino acids. The application discloses application of the polypeptide AIUAP in preparation of a medicine for preventing, assisting in preventing or treating intrauterine adhesion. In the research, a method of tandem mass spectrometry is used to screen endogenous polypeptides differentially expressed in intrauterine adhesion tissues and normal proliferative endometrial tissues, and it is found that the polypeptide AIUAP highly expressed in the intrauterine adhesion tissues can inhibit formation of fibrosis. Since the AIUAP has the characteristics of small molecular weight, self-source and small toxicity, the AIUAP can become an important auxiliary medicine for preventing and treating intrauterine adhesion.

The invention discloses pyruvate carboxylase (PC) serving as a biomarker for detecting endometriosis and application of the pyruvate carboxylase (PC) to treatment of the endometriosis. The biomarker can be used for detecting the expression level of PC in an endometrial tissue sample through an immunohistochemical method, and when the IHC score is greater than or equal to 4, a subject is judged to be at a high risk of endometriosis or suffered from the endometriosis. Meanwhile, the invention provides an application of drugs (including specific siRNA, ZY-444, octyl gallate and the like) for inhibiting PC expression in treatment of endometriosis, and a corresponding treatment method. The invention provides a new biomarker, target spot and scheme for detection and treatment of endometriosis, and has important clinical application value.

The invention relates to the technical field of medical equipment, in particular to a sampling tool for endometrium biopsy and a sampling method.The sampling tool comprises a suction tube, a scraper composed of a plurality of scraping wires is arranged at the far end of the suction tube, and one end of the scraper is inserted into an opening in the far end of the suction tube and connected with the suction tube; a channel for endometrial tissues to enter and exit is arranged between the scraper and the inner wall of the suction tube; the near end of the suction pipe is provided with a pressure adjusting part used for adjusting the pressure intensity in the suction pipe. The scraping wires extend in the axial direction of the suction pipe, the two ends, in the same direction, of the multiple scraping wires are fixedly connected together, and the middles of the multiple scraping wires are spliced to form a hollow ellipsoid structure. The problem that in the suction process of a suction tube in the prior art, in the suction process, a suction inlet is directly covered and blocked by endometrial tissue which is not separated, and contusion is caused to local tissue in a blocked area is solved.

This utility model discloses a disposable endometrial sampler, including an outer tube, a negative pressure suction head connected to one end of the outer tube by a thread, and a sampling bottle connected to one end of the outer tube by a thread. The negative pressure suction head and the sampling bottle are sequentially installed inside the outer tube. A core rod is inserted inside the outer tube, and a silicone ring is provided at the end of the core rod inside the outer tube. The core rod pulls the silicone ring to move inside the outer tube, so that endometrial tissue is sucked into the outer tube through the negative pressure suction head. This utility model uses the sampling bottle to directly obtain endometrial tissue inside the outer tube, reducing the loss and contamination of endometrial tissue collected inside the outer tube during the testing and transfer process.

The invention discloses a noninvasive biomarker related to an endometrial periimplant window phase and application of the noninvasive biomarker. The biomarker comprises 150 miRNAs (micro Ribonucleic Acid), namely, hsa-miR-1290, hsa-miR-511-3p, hsa-miR-1246, hsa-miR-371b-5p, hsa-miR-887-3p, hsa-miR-874-3p, hsa-miR-181a-3p, hsa-miR-873-3p and the like, and is characterized in that the miRNAs can be used for preparing the biomarker. The marker disclosed by the invention can be used for non-invasively and accurately judging whether endometrial tissues have receptivity or not, and has important significance on whether an embryo is successfully transplanted or not.

Provided herein include synthetic endometrial tissues and uterus-like structures for assessing embryo implantation and growth in vitro. Provided herein also include methods and devices for making the synthetic endometrial tissues and uterus-like structures and uses thereof to culture embryos (e.g., human embryos). The methods and synthetic endometrial tissues and structures generated herein can be used to culture pre-implantation embryos (e.g., human embryos) to reach a post-implantation stage.

The invention discloses a traditional Chinese medicine composition for treating thin endometrial reproductive disorder infertility, which is prepared from the following raw material medicines in parts by weight: 20-30 parts of prepared rehmannia root, 10-15 parts of Chinese angelica, 10-15 parts of raw dogwood, 10-12 parts of parched white peony root, 4-6 parts of glossy privet fruit, 4-6 parts of yerbadetajo herb, 4-6 parts of cortex lycii radicis, 10-12 parts of moutan bark, 4-6 parts of golden cypress, 10-12 parts of raw rehmannia root and 10-15 parts of poria cocos. , 10-20 parts of fried rhizoma atractylodis macrocephalae, 10-15 parts of fried eucommia ulmoides and 10-15 parts of salted radix dipsaci. Compared with an existing medicine for treating thin endometrial type reproductive disorder infertility, the traditional Chinese medicine composition can effectively increase the endometrial thickness and improve the endometrial receptivity of a thin endometrial infertility patient, and is excellent in treatment effect, low in side effect and good in application prospect.

The invention provides application of hesperetin in preparation of a medicine for treating intrauterine adhesion, and belongs to the technical field of endometrial repair. It is found that hesperetin can promote endometrial regeneration, inhibit endometrial fibrosis and promote endometrial tissue angiogenesis and can be used for preparing the medicine for preventing and / or treating intrauterine adhesion. And hesperetin is a natural flavone compound, exists in various citrus fruits, has excellent safety and a wide source, and has a good application prospect.

This invention relates to an organoid microarray that simulates the immune microenvironment of multiple organs affected by endometriosis. The microarray comprises a chip with three spatially independent cell culture chambers connected by a series channel: an ovarian organoid culture chamber, a peritoneal culture chamber, and an intestinal organoid culture chamber. Each cell culture chamber has a fluid channel in both its upper and lower layers. This invention also provides a method for organ culture using the organoid microarray that simulates the immune microenvironment of multiple organs affected by endometriosis. Its advantages include: simultaneously connecting ectopic endometrial organoids with three target organs; simultaneously simulating the implantation and invasion process of shed endometrial tissue under the influence of the immune microenvironment and in different organs; and constructing a mixed organoid including glandular and stromal cells to explore the interactions and influences between cells of multiple organs and tissues. This is of great significance for preventing endometriosis from affecting vital organs and for discovering new therapeutic targets.

The application provides application of hydroxysafflor yellow A in preparation of medicines for preventing, treating and / or relieving endometriosis, and belongs to the technical field of biological medicines. The application provides application of hydroxysafflor yellow A in preparation of medicines for preventing, treating and / or relieving endometriosis. Hydroxysafflor yellow A can inhibit migration and / or diffusion of endometriosis cyst, inhibit migration, invasion and abnormal planting of endometrial tissue and / or endometriosis cells outside the uterine cavity, relieve inflammatory reaction caused by endometriosis, and effectively curb lesion invasion and disease progression of endometriosis. As a main active component of safflower, hydroxysafflor yellow A provides a new direction for manufacturing new medicines for treating endometriosis by using safflower.

The invention relates to the technical field of image processing, in particular to a P53 mutation classification method and system for an endometrial cancer pathological section, and the method comprises the steps: carrying out the cutting of a full-view section of endometrial tissue, obtaining a plurality of image blocks, and recording the initial position information of the image blocks; performing feature extraction on each image block to obtain a feature vector of each image block; inputting all the feature vectors and the initial position information into a feature classification model to obtain a corresponding classification result; the feature classification model is used for performing sequence splicing on the feature vectors and inserting a category token to obtain a feature sequence; extracting context information of the feature sequence, and performing multi-scale feature extraction on the context information to obtain a multi-scale comprehensive vector; and obtaining a corresponding classification result based on the multi-scale comprehensive vector and all the initial position information. According to the embodiment of the invention, related personnel can be assisted to more accurately judge whether P53 mutation occurs in the endometrial cancer pathological section or not.

The invention belongs to the technical field of animal models, and particularly relates to a preparation method for constructing a rat embryo implantation failure model based on streptococcus agalactiae. The method comprises the following steps: culturing a streptococcus agalactiae strain with the number of BNCC336970 by using a solid culture medium containing sheep blood, adjusting the concentration of a bacterial solution to 1 * 10 < 8 > CFU / mL, and carrying out vaginal perfusion on an SPF-grade female SD rat every day for 21 days continuously. And after the perfusion is finished, the female mouse is mated with the male mouse at the early oestrus stage, the detected vaginal suppository is marked as the 0.5 th day of pregnancy, the mouse is killed at the 7.5 th day of pregnancy, and the model is evaluated by counting the embryo implantation quantity and detecting the expression level of endometrial tissue receptivity factors MMP9 and VEGF (Vascular Endothelial Growth Factor). A clinical pathogen pathogenic mechanism is simulated through a genital tract infection way for the first time, and the problem of physiological status deviation caused by traditional hormone intervention, immune agonists or genetic engineering methods is solved. The constructed model can stably induce the obvious reduction of the embryo implantation number and the reduction of endometrial receptivity, and provides a standardized tool for the pathological mechanism research of infectious embryo implantation failure and the screening of therapeutic drugs.

The application discloses pyruvate carboxylase (PC) as a biomarker for detecting endometriosis and application of the biomarker in treating endometriosis. The biomarker can be used for detecting the expression level of PC in an endometrial tissue sample by an immunohistochemical method, and when the IHC score is greater than or equal to 4, the subject is determined to be at high risk of or suffering from endometriosis. Meanwhile, the application provides application of a drug (including specific siRNA, ZY-444, octyl gallate and the like) for inhibiting the expression of PC in treating endometriosis and a corresponding treatment method. The application provides a new biomarker, target and scheme for detecting and treating endometriosis, and has important clinical application value.

The invention provides application of a vitamin-magnesium compound in preparation of a medicine for preventing and treating abortion in a pregnancy preparation period and an early pregnancy period and a preparation, and relates to the technical field of biological medicines. The vitamin-magnesium compound takes an organic matter as an organic ligand of the magnesium-based coordination chelate, and the organic matter is any one of vitamin B13, vitamin B3 and vitamin C; the magnesium-based coordination chelate acts on endometrial stromal cells to promote cell proliferation so as to promote normal implantation of embryos; the magnesium-based coordination chelate acts on endometrial tissue vascular endothelial cells to promote cell proliferation so as to promote angiogenesis and meet embryo nutrition supply; the magnesium-based coordination chelate acts on endometrial tissue macrophages, M1 type macrophages are polarized to M2 type macrophages, immune tolerance to embryos is promoted, and the embryos are prevented from being attacked by maternal immune cells to affect normal growth and development.

The invention belongs to the technical field of biology, and particularly relates to application of an SPON2 gene or a protein thereof as a target spot in diagnosis or treatment of endometriosis. Through multi-omics and single cell level data support and clinical sample inspection, the correlation between SPON2 and endometriosis (EM) is analyzed for the first time, and it is revealed that proliferation, invasion and migration capacities of in-situ endometrial and ectopic endometrial fibroblasts of endometriosis patients can be enhanced through high expression of SPON2. By inhibiting the expression of the SPON2 gene or inhibiting the function of the SPON2 protein, the proliferation and invasion ability of endometrial tissues and the migration, invasion and fibrosis of lesions are reduced, and the condition of endometriosis is improved, which prompts that the SPON2 gene or the protein thereof can be used as a diagnosis or treatment target. And a new thought and direction are provided for clinical diagnosis and targeted therapy of endometriosis.